---
document_datetime: 2023-09-21 21:42:57
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/novoseven-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: novoseven-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.271268
conversion_datetime: 2025-12-15 00:14:42.550136
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## NovoSeven

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0119            | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority | 23/02/2023                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0118            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                 | 05/01/2023   |            | SmPC                   |                                                          |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------------------------------------|
| II/0117            | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                               | 01/09/2022   | n/a        |                        |                                                          |
| II/0116            | Extension of indication to include treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is also updated in accordance. Version 8.0 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 22/04/2022   | 24/05/2022 | SmPC and PL            | Please refer to Scientific Discussion 'NovoSeven II-116' |
| PSUSA/1245/ 202012 | Periodic Safety Update EU Single assessment - eptacog alfa                                                                                                                                                                                                                                                                                                                                                                     | 02/09/2021   | n/a        |                        | PRAC Recommendation - maintenance                        |
| IA/0115            | To delete the vial-vial presentations (EU/1/96/006/004-007) for NovoSeven, Powder and solvent for solution for injection 1 mg, 2mg, 5 mg, 8 mg. B.II.e.5.b - Change in pack size of the finished                                                                                                                                                                                                                               | 07/06/2021   | 29/09/2021 | SmPC, Labelling and PL |                                                          |

<div style=\"page-break-after: always\"></div>

|           | product - Deletion of a pack size(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0109/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a | 14/01/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|         | variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0113 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                           | 18/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0112 | B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                            | 18/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0111 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                      | 06/11/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0110 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                      | 09/10/2020 | 29/09/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0106 | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol | 17/10/2019 | 16/10/2020 | SmPC                             | In hospital settings only, reconstitution must take place in controlled and validated aseptic conditions by adequately trained staff. Under these conditions, chemical and physical stability has been demonstrated for 24 hours at 25°C when stored in a 50 ml syringe (polypropylene). If not used immediately, the conditions prior to use are the responsibility of the user and the in-use storage time must not be longer than as stated above. For more information please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IB/0108     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 25/07/2019   | n/a        |             |                                                                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------|
| IA/0107/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/07/2019   | n/a        |             |                                                                |
| II/0104     | Extension of Indication to include patients with Glanzmann's thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available, based on a prospective observational registry and literature references. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes in section 4.8 of the SmPC and in Package Leaflet. The updated RMP version 7.1 has been agreed within this procedure. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 18/10/2018   | 20/11/2018 | SmPC and PL | Please refer to Scientific Discussion EMEA/H/C/000074/II/0104. |
| PSUSA/1245/ | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/07/2018   | n/a        |             | PRAC Recommendation - maintenance                              |

<div style=\"page-break-after: always\"></div>

| 201712    | eptacog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| II/0101/G | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished | 17/05/2018 | n/a | product - Other variation |
| IB/0105   | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                                                                                                                                                                                                                     | 15/05/2018 | n/a |                           |
| IA/0102   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                           | 14/12/2017 | n/a |                           |
| IG/0870   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                          | 27/11/2017 | n/a |                           |
| IA/0099   | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                            | 28/04/2017 | n/a |                           |

<div style=\"page-break-after: always\"></div>

| IB/0097   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                    | 03/02/2017   | n/a        |                                  |            |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|------------|
| IB/0098/G | This was an application for a group of variations. B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor an approved test procedure                                                                                                                                                                                             | 11/01/2017   | n/a        |                                  | changes to |
| II/0092   | Update of section 4.4 of the SmPC in order to delete sucrose warning (also affecting section 2 of the SmPC). The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes/corrections and updates in sections 4.8, 6.4, 6.5 and 6.6 of the SmPC and in the Package Leaflet. Moreover, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10 (combined SmPC has been introduced). C.I.4 - Change(s) in the SPC, Labelling or PL due to | 08/12/2016   | 26/01/2017 | SmPC, Annex II, Labelling and PL |            |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| II/0093   | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                    | 10/11/2016 | n/a |                  |
| IA/0096   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                             | 15/09/2016 | n/a |                  |
| IB/0095   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                               | 28/07/2016 | n/a |                  |
| IB/0094/G | This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                     | 19/07/2016 | n/a |                  |
| II/0089   | Submission of the Final Study Report NN7025-3601: Prospective Observational Study on NovoSeven room temperature (VII25) in patients with Haemophilia A and B. The study was intended to monitor prospectively for decreased therapeutic response and the development of neutralising antibodies towards FVII (FVII inhibitors). The submission of this study MEA 046.4 and an updated RMP | 26/05/2016 | n/a | report addresses |

<div style=\"page-break-after: always\"></div>

|           | version 6.1 is provided. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----|
| II/0091/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                            | 25/02/2016 | n/a        |                                  |     |
| II/0090/G | This was an application for a group of variations. Deletion of the 3 strengths; 1.2 mg (60 KIU), 2.4 mg (120 KIU), 4.8 mg (240 KIU) - MA numbers EU/1/96/006/001-003. The SmPC, labelling and Package Leaflet have been revised accordingly with deletion of the affected presentations. Update of the conditions in Annex II; consequential deletion of the content in the Annex IID related to additional risk minimisation measures (potential risk of medication errors related to the 3 strengths above). Consequential deletion of Annex 127a. | 21/01/2016 | 26/01/2017 | SmPC, Annex II, Labelling and PL | N/A |

<div style=\"page-break-after: always\"></div>

|                    | C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0088          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                     | 18/08/2015 | n/a |                                   |
| IA/0087            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                          | 29/07/2015 | n/a |                                   |
| PSUSA/1245/ 201412 | Periodic Safety Update EU Single assessment - eptacog alfa                                                                                                                                                                                                                                                                                                             | 09/07/2015 | n/a | PRAC Recommendation - maintenance |
| IB/0084            | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                           | 03/03/2015 | n/a |                                   |
| II/0083            | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                             | 26/02/2015 | n/a |                                   |
| II/0082            | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch                                                                                                                                                                                                                         | 20/11/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0081   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/09/2014 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUV/0080 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/07/2014 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| N/0079    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/05/2014 | 26/01/2017 | Labelling and PL                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0073   | Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC with information from an observational registry F7HAEM-3578. The Package Leaflet is updated accordingly. Editorial amendments have been proposed throughout the PI. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. The requested variation proposed amendments to the Summary of Product Characteristics, Annex II, Labelling and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/11/2013 | 18/12/2013 | SmPC, Annex II, Labelling and PL | In an observational registry (F7HAEM-3578) covering subjects with congenital FVII deficiency, the median dose for long term prophylaxis against bleeding in 22 paediatric patients (below 12 years of age) with Factor VII deficiency and a severe clinical phenotype was 30 µg/kg (range 17 µg/kg to 200 µg/kg; the dose most often used was 30 µg/kg in 10 patients) with a median dose frequency of 3 doses per week (range 1 to 7; the dose frequency most often reported was 3 per week in 13 patients). In the same registry 3 out of 91 surgical patients experienced thromboembolic events. The summary of product characteristics has been updated to include these data and the relevant pharmacokinetic information. It is also stated under posology recommendations that limited clinical experience in long term prophylaxis has been gathered in the paediatric population below 12 years of age, with a severe clinical phenotype. Dose and frequency of injections for prophylaxis should be |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             | based on clinical response and adapted to each individual. Changes have been made to the product information to bring it in line with the Quality review of document (QRD) template version 9.0.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0078   | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                  | 06/12/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0074   | Update of section 4.5 of the SmPC in order to include a recommendation not to combine Factor VII with FXIII and section 5.3 to include the relevant preclinical information. The Package Leaflet is updated accordingly. An editorial change was made to section 4.8 of the SmPC. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 25/04/2013 | 18/12/2013 | SmPC and PL | Results from a cardiovascular model study in cynomolgus monkeys already submitted and evaluated within the marketing application for the product NovoThirteen, where rFVIIa was administered concomitantly with rFXIII suggest that the combination of the two products could have a synergic effect which could lead to thrombus and death. The results are highlighted in section 5.3 of the SmPC. As a consequence a recommendation not to combine the products is included in section 4.5 of the SmPC. This update of the product information of Novoseven is in line with the recommendations in the product information of NovoThirteen. An editorial change was made for clarification in section 4.8 of the SmPC to make reference to 'reports of inhibitory antibodies against NovoSeven …'. |
| IG/0280   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                           | 17/04/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0076/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                      | 22/03/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | - Submission of a new or updated Ph. Eur. Certificate of suitability - Updated certificate an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        | B.III.1.b.3 TSE from   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------|
| IA/0075   | B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/03/2013 | n/a        |                        |                        |
| II/0071   | Change to the active substance specification B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/01/2013 | n/a        |                        |                        |
| II/0072/G | This was an application for a group of variations. B.II.e.1.b.2 - Change in immediate packaging of the finished product - Type of container - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products | 20/09/2012 | 24/10/2012 | SmPC, Labelling and PL |                        |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   |            |            |             |                                                                                                                      |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------|
| II/0068 | Changes to the active substance manufacturing process. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/02/2012 | 16/02/2012 |             |                                                                                                                      |
| II/0069 | The MAH has submitted a type II variation to update section 4.8 with the inclusion of intracardiac                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/11/2011 | 13/01/2012 | SmPC and PL | A safety signal has been identified and as a consequence the MAH has submitted a type II variation to update section |

<div style=\"page-break-after: always\"></div>

|           | thrombus as an example of arterial thromboembolic events - at the request of the CHMP following the assessment of the latest PSUR. An editorial amendment was also introduced. The Package leaflet was updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |            | 4.8 with the inclusion of intracardiac thrombus as an example of arterial thromboembolic events - at the request of the CHMP. The frequency was classified as 'not known'. The section 4 of the Package leaflet was also updated.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0070   | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                            | 25/11/2011 | n/a        |                                                                                                                                                                                                                                     |
| II/0067   | Extension of active substance storage time. B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol                                                                                                                                                                                                                                              | 17/11/2011 | 17/11/2011 |                                                                                                                                                                                                                                     |
| IB/0066   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                                    | 06/06/2011 | n/a        |                                                                                                                                                                                                                                     |
| II/0065/G | This was an application for a group of variations. Changes to the active substance manufacture and in-                                                                                                                                                                                                                                                                                                                                                                                    | 14/04/2011 | 29/04/2011 |                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | process testing. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS   |            |            |                              |                                                      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|------------------------------------------------------|
| IG/0048/G | This was an application for a group of variations. C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                              | 11/03/2011 | n/a        | SmPC, Annex II and Labelling |                                                      |
| II/0063   | Changes to the drug substance manufacturing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/10/2010 | 03/11/2010 |                              | Changes to the drug substance manufacturing process. |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064/G | This was an application for a group of variations. 1) Addition of single dose presentation of Novoseven 8 mg. 2) Extension of shelf life of the 1, 2 and 5 mg presentations from 24 to 36 months. B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, and biological/immunological multidose parenteral medicinal products B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol | 23/09/2010 | 28/10/2010 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                      |
| IA/0062   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/06/2009 | n/a        | Annex II                         |                                                                                                                                                                                                                      |
| II/0060   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/04/2009 | 28/05/2009 | SmPC and PL                      | Further to a CHMP request to bring all NovoSeven presentations in line and in accordance with current guidelines the MAH submitted a type II variation concerning sections 4.6, 4.8, and 4.9. In addition, following |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| a PSUR review by the CHMP, and a MAH safety analysis to  their own database including clinical trials and Post  Marketing Experience data the MAH updated section 4.8  and section 4.9.  In sections 4.6 the paragraph regarding lactation was  amended as follows:  It is unknown whether rFVIIa is excreted in human breast  milk. The excretion of rFVIIa in milk has not been studied  in animals. A decision on whether to continue/discontinue  breast-feeding or to continue/discontinue therapy with  NovoSeven should be made taking into account the benefit  of breast-feeding to the child and the benefit of NovoSeven  therapy to the woman.  An updated number of cases of overdose was introduced in  section 4.9 with other minor modifications.  Finally section 4.8 was completely revised in accordance  with the safety analysis of post marketing and clinical trials  as well as the current SmPC guideline recommendations. In  particular, the table listing undesirable effects was revised  both for frequency and nature of adverse drug reactions  mentioned.  Specific subsections were also introduced under the table in  section 4.8. In particular, a higher risk of arterial  thrombotic events observed from a meta-analysis of pooled  data from placebo controlled trials was added in section  4.8, with a clear statement that NovoSeven should not be  used outside the approved indications.  The Package Leaflet has been updated accordingly.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                                  | Furthermore, minor wording changes have been introduced to the Product Information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0061 | Move of QC testing site. Analytical procedures and specifications remain the same. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2009 | 28/01/2009 |                                  | Move of QC testing site. Analytical procedures and specifications remain the same.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0057 | The MAH has applied to amend the Product Information texts of all NovoSeven presentations in accordance with current guidelines, further to a request of the CHMP in the context of the procedure EMEA/H/C/0074/X/55 (FUM 045 and FUM 047). Consequently, minor changes are introduced in the sections 2, 4.1, 4.2, 4.3, 4.4, 4.6, 4.8, 6.1, 6.4, 6.5 and 6.6 of the SPC, Annex II and Annex III are updated. Furthermore, the MAH has taken the opportunity to align the Product Information texts for the NovoSeven presentations (EU/1/96/006/001- 003) with the Product Information texts for the new room temperature stable formulation (EU/1/96/006/004-006). Update of Summary of Product Characteristics, | 24/07/2008 | 25/08/2008 | SmPC, Annex II, Labelling and PL | The MAH has applied to amend the Product Information texts of all NovoSeven presentations in accordance with current guidelines, further to a request of the CHMP in the context of the procedure EMEA/H/C/0074/X/55 (FUM 045 and FUM 047). Consequently, minor changes are introduced in the sections 2, 4.1, 4.2, 4.3, 4.4, 4.6, 4.8, 6.1, 6.4, 6.5 and 6.6 of the SPC, Annex II and Annex III are updated. Furthermore, the MAH has taken the opportunity to align the Product Information texts for the NovoSeven presentations (EU/1/96/006/001-003) with the Product Information texts for the new room temperature stable formulation (EU/1/96/006/004-006). |
| IA/0059 | Replacement of vial adaptor for 1.2, 2.4 and 4.8 mg presentations. IA_43_a_01_ Add./replacement/del. of measuring or administration device - addition or replacement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/08/2008 | n/a        | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0058   | Approval of an alternate freeze-dryer for the medicinal product and consequential upscale of batch size. Quality changes                                                                                                                 | 24/07/2008   | 29/07/2008   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0055    | Approval of the extension of the drug product range of Novoseven with three presentations of a new below 25°C stable formulation and new strengths of 1, 2 and 5 mg per vial. Annex I_2.(c) Change or addition of a new strength/potency | 21/02/2008   | 25/04/2008   | SmPC, Labelling and PL | In order to make storage and transport of NovoSeven more convenient for the users, a new drug product formulation allowing storage <25°C has been developed. The new formulation involves the introduction of two new excipients. Furthermore, in order to facilitate the calculation of the dose needed for the individual patient, the drug product presentations of the new formulation will comprise three single use vials of 1, 2, and 5 mg of lyophilized rFVIIa per vial. Reconstitution with the appropriate volumne of the Histidine solvent will provide 1.0 mg rFVIIa/ml for each strength. Comparative characterisation studies confirmed that the change in formulation does not lead to changes in the physical and chemical characteristics of rFVIIa. There are no changes of indications, dose recommendations, undesirable effects or warnings and precautions, as compared to the current formulation of NovoSeven. Overall, based on the available data, the benefit/risk of the new formulation of NovoSeven was considered positive. A risk management plan was submitted. The CHMP, having considered the data submitted, was of the opinion that pharmacovigilance activities in addition to the use of routine pharmacovigilance were needed to investigate further some of the safety concerns and that additional risk |

<div style=\"page-break-after: always\"></div>

|         |                                                                                |            |            |             | minimisation activities were required.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056 | Change(s) to the test method(s) and/or specifications for the active substance | 13/12/2007 | 19/12/2007 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0054 | Update of Summary of Product Characteristics                                   | 19/07/2007 | 03/09/2007 | SmPC        | The MAH applied for a type II variation to update section 5.2 Pharmacokinetic properties of the SPC based on the results from two pharmacokinetic studies. The pharmacokinetics of NovoSeven were investigated in 35 healthy Caucasian and Japanese healthy subjects. The pharmacokinetic profiles indicated dose proportionality and were similar across sex and ethnic groups. In a study in 12 paediatric (2-12 years) and 5 adult patients with haemophilia A and B with inhibitors in non bleeding state, dose proportionality was established in children for the investigated doses of 90 and 180 ?g per kg body weight. Mean clearance was approximately 50% higher in paediatric patients relative to adults and increased towards a lower age. Consequently, section 4.2 of the SPC was updated with regards to dosing information in children as follows: \"Dosing in children Current clinical experience does not warrant a general differentiation in dosing between children and adults, although children have faster clearance than adults. Therefore, higher doses of rFVIIa may be needed in paediatric patients to achieve similar plasma concentrations as in adult patients (see section 5.2).\" Minor editorial changes to the SPC are also included. |
| II/0053 | Update of Summary of Product Characteristics and Package Leaflet               | 24/01/2007 | 05/03/2007 | SmPC and PL | The CHMP adopted an update of section 4.2 'Posology and method of administration' in the SPC with an alternate dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                              |            |            |             | recommendation. In addition to the current recommendation of 90 g /kg, which may be repeated as required, a single dose of 270 g/kg/body weight is recommended for the treatment of mild to moderate bleeding episodes in haemophilia A or B patients with inhibitors to factor VIII or factor IX in order to achieve rapid haemostasis and reduce the number of injections. This is based on clinical data from 2 double-blind clinical studies and relevant literature data. The section 4.4 is updated with a warning for the elderly population since there is no clinical experience in this population. The PL is updated accordingly.   |
|---------|------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0052 | Update of Summary of Product Characteristics and Package Leaflet                                                             | 16/11/2006 | 04/01/2007 | SmPC and PL | The MAH applied for a type II variation to add information on 'hepatic thrombotic events' in section 4.8 of the SPC in order to clarify that in the vast majority of cases these patients were predisposed due to liver disease or liver surgery. In addition, the MAH took the opportunity to make a few minor editorial and linguistic changes in the SPC and the PL.                                                                                                                                                                                                                                                                        |
| II/0048 | Change(s) to the manufacturing process for the active substance                                                              | 16/11/2006 | 21/11/2006 |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0051 | Changes in the manufacturing process of the active substance Change(s) to the manufacturing process for the active substance | 18/10/2006 | 23/10/2006 |             | Changes in the manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0046   | Additional manufacturing site of drug substance Change(s) to the manufacturing process for the active substance   | 27/07/2006   | 21/08/2006   | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047   | Update of Summary of Product Characteristics and Package Leaflet                                                  | 28/06/2006   | 04/08/2006   | SmPC and PL                      | Update of Section 4.8 of the SPC to include cases of anaphylactic reactions reported in the PMS following the 13th PSUR. The package leaflet has been updated accordingly. In addition the MAH proposed minor changes in sections 4.2, 5.1, 5.2 and package leaflet.                                                                                                                                                                                                                                                                            |
| IB/0049   | IB_30_b_Change in supplier of packaging components - replacement/addition                                         | 28/06/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0045   | Change(s) to the manufacturing process for the finished product                                                   | 23/02/2006   | 07/03/2006   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0043    | Renewal of the marketing authorisation.                                                                           | 14/12/2005   | 09/02/2006   | SmPC, Annex II, Labelling and PL | Unlimited validity of the MA granted in February 2006 subject to clinical follow up measures. The MAH should submit PSURs every 18 months until further notice.                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0041   | Introduction of new device for reconstitution and a changed package. Change(s) to container                       | 13/10/2005   | 16/11/2005   | SmPC, Labelling and PL           | This variation recomends the introduction of new device for reconstitution and a changed package, as applied by the MAH. The MAH proposed a new vial adaptor to facilitate the transfer of water from the solvent vial to the NovoSeven vial. The change of device concerns a substitution of the current transfer needle with a needle-free vial adaptor for the reconstitution process of NovoSeven. Due to different size of the proposed vial, the dimensions of the outer packaging box are changed. Moreover, in the redesigned packaging |

<div style=\"page-break-after: always\"></div>

|         |                                                                                |            |            | box the current plastic tray is replaced by a carton tray, and a separate inner-carton for the powder and solvent vials is introduced for the fixation of the vials. As a consequence of the changes, the SPC and PIL have also been adapted. The MAH proposed a new vial adaptor to facilitate the transfer of water from the solvent vial to the NovoSeven vial. This change aims to improve the current reconstitution procedure preventing the risk of the current transfer needle with stick injuries in patients and health care professionals. Changes related to the reconstitution procedure are included in the package leaflet. Pictures have also been added to make the description of the reconstitution procedure more user-friendly. On the basis of the information provided by the MAH, the CHMP recomended the aproval of the new proposed vial adaptor and the change on the dimensions of the packaging box.   |
|---------|--------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0039 | Change(s) to the test method(s) and/or specifications for the finished product | 15/09/2005 | 03/10/2005 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0038 | Change(s) to the test method(s) and/or specifications for the active substance | 15/09/2005 | 03/10/2005 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0040 | Change(s) to shelf-life or storage conditions                                  | 21/04/2005 | 27/04/2005 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0034 | Quality changes                                                                | 21/10/2004 | 26/10/2004 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0035   | Update of or change(s) to the pharmaceutical documentation                                                                                                               | 29/07/2004   | 03/08/2004   |                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| II/0031   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                         | 25/09/2003   | 27/01/2004   | SmPC and PL            |
| II/0030   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                         | 25/09/2003   | 27/01/2004   | SmPC, Labelling and PL |
| II/0029   | Extension of Indication                                                                                                                                                  | 22/10/2003   | 27/01/2004   | SmPC and PL            |
| II/0028   | Extension of Indication                                                                                                                                                  | 22/10/2003   | 27/01/2004   | SmPC and PL            |
| II/0027   | Changes to the shelf life of the powder for injection to 36 months; changes to the shelf life of the solvent to 36 months. Change(s) to shelf-life or storage conditions | 24/07/2003   | 08/10/2003   | SmPC                   |
| I/0032    | 24_Change in test procedure of active substance                                                                                                                          | 22/08/2003   | 22/09/2003   |                        |
| I/0025    | 15_Minor changes in manufacture of the medicinal product                                                                                                                 | 20/02/2003   |              | 10/03/2003             |
| I/0024    | 16_Change in the batch size of finished product                                                                                                                          | 20/02/2003   | 10/03/2003   |                        |
| I/0023    | 24_Change in test procedure of active substance 25_Change in test procedures of the medicinal product                                                                    | 21/11/2002   | 09/12/2002   |                        |

<div style=\"page-break-after: always\"></div>

| I/0022   | 18_Synthesis or recovery of non-pharmacopoeial excipients in the medicinal products                                              | 15/07/2002   | 15/07/2002   |             |
|----------|----------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|
| I/0021   | 12_Minor change of manufacturing process of the active substance                                                                 | 25/04/2002   | 29/04/2002   |             |
| I/0020   | 12_Minor change of manufacturing process of the active substance                                                                 | 25/04/2002   | 29/04/2002   |             |
| II/0018  | Update of Summary of Product Characteristics and Package Leaflet                                                                 | 01/03/2001   | 20/06/2001   | SmPC and PL |
| I/0019   | 26_Changes to comply with supplements to pharmacopoeias                                                                          | 13/03/2001   | 06/04/2001   |             |
| II/0015  | Change(s) to the test method(s) and/or specifications for the finished product                                                   | 19/10/2000   | 28/11/2000   |             |
| I/0016   | 04_Replacement of an excipient with a comparable excipient                                                                       | 15/09/2000   | 21/10/2000   |             |
| II/0014  | Update of Summary of Product Characteristics and Package Leaflet                                                                 | 29/07/1999   | 08/12/1999   | SmPC and PL |
| I/0013   | 11_Change in or addition of manufacturer(s) of active substance 12_Minor change of manufacturing process of the active substance | 23/02/1999   | 08/03/1999   |             |
| I/0012   | 11_Change in or addition of manufacturer(s) of active substance                                                                  | 23/02/1999   | 08/03/1999   |             |

<div style=\"page-break-after: always\"></div>

|         | change of manufacturing process of the substance                                                                                          |            |            |                        | 12_Minor active   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| II/0011 | Update of or change(s) to the pharmaceutical documentation Change(s) to the test method(s) and/or specifications for the active substance | 27/01/1999 | 08/02/1999 |                        |                   |
| II/0010 | Change(s) to the test method(s) and/or specifications for the active substance                                                            | 27/01/1999 | 08/02/1999 |                        |                   |
| II/0009 | Change(s) to shelf-life or storage conditions                                                                                             | 27/01/1999 | 08/02/1999 |                        |                   |
| II/0007 | Change(s) to container                                                                                                                    | 23/07/1998 | 19/11/1998 | SmPC, Labelling and PL |                   |
| I/0008  | 20_Extension of shelf-life as foreseen at time of authorisation                                                                           | 15/05/1998 | 17/07/1998 | SmPC                   |                   |
| I/0006  | 12_Minor change of manufacturing process of the active substance                                                                          | 24/06/1998 | n/a        |                        |                   |
| II/0001 | Update of Summary of Product Characteristics and Package Leaflet                                                                          | 23/07/1997 | 04/12/1997 | SmPC and PL            |                   |
| I/0004  | 12_Minor change of manufacturing process of the active substance                                                                          | 24/09/1997 | n/a        |                        |                   |
| I/0003  | 12_Minor change of manufacturing process of the active substance                                                                          | 24/09/1997 | n/a        |                        |                   |

<div style=\"page-break-after: always\"></div>

| I/0002   | 12_Minor change of manufacturing process of the active substance   | 24/09/1997   | n/a   |
|----------|--------------------------------------------------------------------|--------------|-------|